UroGen Pharma Says FDA Approves Plan For Rolling NDA Submission For UGN-102 From January 2024

RTTNews | 1142 hari yang lalu
UroGen Pharma Says FDA Approves Plan For Rolling NDA Submission For UGN-102 From January 2024

(RTTNews) - Biotech company UroGen Pharma Ltd. (URGN) announced Tuesday that it has reached agreement with the U.S. Food and Drug Administration (FDA) on plans for submission of a New Drug Application (NDA) for UGN-102 (mitomycin) for intravesical solution.

The FDA indicated that the current clinical development plan for UGN-102, which includes evaluation of duration of complete response (CR) at 12 months from the pivotal ENVISION trial, will support submission of an NDA for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).

The FDA also agreed that the UGN-102 NDA can utilize a rolling review, allowing for early submission of the Chemistry, Manufacturing and Controls (CMC) sections of the NDA, which is planned for January 2024.

If approved, UGN-102 has the potential to introduce a new non-surgical treatment paradigm for LG-IR-NMIBC, a subset of bladder cancer patients characterized by high recurrence rates and the need for multiple surgeries.

The UGN-102 clinical development plan centers around the Phase 3 ENVISION pivotal trial and is supported by robust clinical data from the ATLAS Phase 3 and OPTIMA Phase 2b trials.

baca selengkapnya
UroGen Pharma Files Patent Infringement Lawsuit Against Teva Pharma

UroGen Pharma Files Patent Infringement Lawsuit Against Teva Pharma

Biotech company UroGen Pharma Ltd. (URGN) announced Wednesday that it has filed a lawsuit in the U.S. District Court for the District of Delaware against Teva Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., and Teva Pharmaceutical Industries, Ltd. (TEVA), alleging infringement of U.S. Patent Numbers 9,040,074 and 9,950,069.
RTTNews | 959 hari yang lalu
Australian Market Maintains Early Losses In Mid-market

Australian Market Maintains Early Losses In Mid-market

The Australian market is maintaining its early losses in mid-market moves on Thursday, extending the losses in the previous five sessions, following the mixed cues from Wall Street overnight. The benchmark S&P/ASX 200 is falling to near the 8,750 level, with weakness in mining and energy stocks.
RTTNews | 3 jam 18 menit yang lalu
Asian Markets Trade Mostly Lower

Asian Markets Trade Mostly Lower

Asian markets are trading mostly lower on Thursday, following the mixed cues from Wall Street overnight, with weakness in mining and energy stocks amid tumbling commodity prices. Expectation of more aggressive monetary tightening by the US Fed on interest rates is weighing on market sentiment. Asian markets closed mixed on Wednesday.
RTTNews | 3 jam 26 menit yang lalu
Thai Stock Market May Halt Its Slide On Thursday

Thai Stock Market May Halt Its Slide On Thursday

The Thai stock market has tracked lower in three straight sessions, shedding almost 35 points or 2.2 percent along the way. The Stock Exchange of Thailand now sits just above the 1,470-point plateau although it may find support on Thursday.
RTTNews | 4 jam 56 menit yang lalu
Japanese Market Modestly Higher

Japanese Market Modestly Higher

The Japanese market is trading modestly higher on Thursday, extending the gains in the previous session, following the mixed cues from Wall Street overnight. The Nikkei 225 is moving above the 59,100 level, with gains in index heavyweights and technology stocks partially offset by weakness in financial stocks.
RTTNews | 5 jam 6 menit yang lalu